SCHEMBL24745467

SCHEMBL24745467

COC(=O)c1cc(F)cc2c1nc(C)n2CC(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.37
▸ MAPT P10636 3/20 0.37
▸ HK1 P19367 2/20 0.37
▸ HKDC1 Q2TB90 2/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ KDM4E B2RXH2 3/20 0.36
▸ CACNA1B Q00975 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ TLR7 Q9NYK1 1/20 0.34
▸ PLA2G7 Q13093 1/20 0.34
▸ DCTPP1 Q9H773 1/20 0.34
▸ BRD4 O60885 1/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ JAK3 P52333 1/20 0.33
▸ GAA P10253 1/20 0.32
▸ PKN1 Q16512 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24745459 0.89 ALDH1A1 (0.37) ALDH1A1MAPTHK1HKDC1LMNA
SCHEMBL24745449 0.89 CACNA1B (0.40) ALDH1A1MAPTKDM4ECACNA1BSMN1; SMN2
SCHEMBL24745728 0.88 ALDH1A1 (0.37) ALDH1A1MAPTKDM4ECACNA1BSMN1; SMN2
SCHEMBL24744896 0.87 KDM4E (0.36) ALDH1A1MAPTKDM4ECACNA1BSMN1; SMN2
SCHEMBL24745532 0.87 DCTPP1 (0.38) ALDH1A1MAPTKDM4ECACNA1BSMN1; SMN2
SCHEMBL24745413 0.87 BRD4 (0.38) ALDH1A1MAPTHSD17B10KDM4ECACNA1B
SCHEMBL24745446 0.82 TLR7 (0.35) ALDH1A1MAPTKDM4ECACNA1BSMN1; SMN2
SCHEMBL24744762 0.82 PKN1 (0.47) ALDH1A1MAPTLMNAKDM4ESMN1; SMN2
SCHEMBL29893726 0.82 PKN1 (0.47) ALDH1A1MAPTLMNAKDM4ESMN1; SMN2
SCHEMBL31090575 0.80 PRMT5 (0.35) ALDH1A1KDM4ECACNA1BSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-09-05 — — US disclosed
CN-117957218-A Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins 凯普托尔治疗学股份有限公司 2024-04-30 — — CN disclosed
WO-2022253713-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN MCL1, MDM2, XIAP ALDH1A1 956/4885MAPT 1918/4885HK1 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback